Ocular Discovery

Ocular Discovery is a clinical-stage biopharmaceutical company focused on repurposing established medications for the treatment of ocular surface disorders. The company's primary focus is a proprietary, temperature-stable, topical formulation of dipyridamole, a drug traditionally used for cardiovascular conditions. Ocular Discovery has received regulatory approval in Israel for the symptomatic relief of Dry Eye, Pterygium, and Pinguecula. Its pipeline extends to several other indications, including conjunctivitis and corneal neovascularization, leveraging dipyridamole's anti-inflammatory, anti-angiogenic, and anti-proliferative properties. The company is headquartered in Israel and maintains research collaborations globally, including partnerships with leading ophthalmic centers.